MENU
TRLV
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

TRLV stock forecast, quote, news & analysis

TRLV
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement

Why Trulieve Cannabis Corp. (TRLV) Stock Is Up +42.6% in the Last 30 Days

Key Takeaways

  • TRLV surged approximately 42.6% over the last 30 days, driven by a historic NYSE uplisting and a $50 million share repurchase program.
  • The stock rallied roughly 79% during the most recent quarter, reflecting improving fundamentals and regulatory tailwinds.
  • Trulieve became the first U.S. cannabis company to list on the New York Stock Exchange, a milestone that significantly boosted investor sentiment and institutional visibility.
  • Q1 2026 results showed $287 million in revenue, a 59% gross margin, and positive net income, underscoring operational strength.
  • Medical marijuana's reclassification to Schedule III removed the 280E tax burden, enhancing free cash flow and profitability.
  • Analyst coverage has turned increasingly bullish, with multiple firms raising price targets and maintaining Buy ratings.

Trulieve Cannabis Corp. (TRLV) Company Overview and Market Position

Trulieve Cannabis Corp. is a vertically integrated, multi-state cannabis operator headquartered in Tallahassee, Florida. The company cultivates, processes, manufactures, and retails a broad portfolio of cannabis products, including flower, edibles, vapes, concentrates, topicals, and accessories. Its brand portfolio spans names such as Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One. Trulieve operates dispensaries across Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania, with cultivation and processing facilities in several of those states. With approximately 5,000 employees and a market capitalization exceeding $2 billion, Trulieve is one of the largest and most scaled cannabis operators in the United States. Investors follow the stock closely due to its dominant Florida medical market position, expanding hub strategy, and sensitivity to federal cannabis policy developments.

Trulieve Cannabis Corp. (TRLV) Stock Price Performance: Last 30 Days vs. Quarter

Over the 30-day period ending June 11, 2026, TRLV shares climbed from an adjusted closing price of $8.10 on May 12 to $11.55 on June 11, representing a gain of approximately 42.6%. The rally accelerated sharply in early June following the announcement of the company's NYSE uplisting and share buyback program. Daily trading volumes expanded significantly, with several sessions exceeding 1 million shares traded, reflecting heightened institutional and retail interest.

Zooming out to the quarterly timeframe, the stock's performance is even more striking. From an adjusted close of $6.44 on March 11, 2026, TRLV advanced roughly 79% to the June 11 level. The quarter was characterized by a steady upward grind through April, a brief consolidation in early May, and a powerful breakout in June. This multi-month trend was underpinned by improving financial results, regulatory progress, and growing confidence in the company's strategic direction.

What Drove TRLV Stock Price in the Last 30 Days

The primary catalyst for the 30-day surge was Trulieve's historic transition to the New York Stock Exchange. On June 5, the company announced that its subordinate voting shares would begin trading under the ticker TRLV on June 10, making it the first U.S. cannabis company to list on the NYSE. The uplisting from the OTCQX market represented a major validation for the cannabis sector and opened the door to a broader universe of institutional investors who are restricted from trading over-the-counter securities.

Simultaneously, Trulieve's Board of Directors authorized a share repurchase program of up to $50 million, or approximately 5% of outstanding shares. The buyback announcement signaled management's confidence in the company's intrinsic value and commitment to returning capital to shareholders. These two events, occurring in rapid succession, created a powerful momentum shift that drove the stock sharply higher.

Additional support came from analyst activity. Alliance Global Partners raised its price target and reiterated a Buy rating, while Roth MKM and Haywood also maintained constructive outlooks. The company's Q1 2026 earnings, reported in early May, provided a fundamental backbone for the rally: revenue of $287 million, a 59% gross margin, positive net income of $2 million, and adjusted EBITDA of $100 million demonstrated that Trulieve could deliver profitability at scale.

What Drove TRLV Stock Performance Over the Last Quarter

The broader quarterly advance was fueled by a confluence of regulatory, operational, and strategic developments. The most significant regulatory shift was the Drug Enforcement Administration's decision to reclassify state-regulated medical marijuana to Schedule III, effectively eliminating the onerous 280E tax provision that had previously prevented cannabis companies from deducting ordinary business expenses. This change immediately improved Trulieve's after-tax cash flow and earnings profile.

Operationally, Trulieve continued to execute its hub strategy, maintaining dominant market share in Florida while selectively expanding in states such as Georgia, Ohio, and Maryland. The company's domestication from British Columbia to Delaware, announced in May, further aligned its corporate structure with U.S. capital markets and removed a technical barrier to the NYSE listing. Throughout the quarter, investor sentiment toward cannabis stocks improved broadly, with peers such as GTBIF, CURA.TO, and VRNO.NE also experiencing upward momentum, though Trulieve's NYSE catalyst set it apart.

Trending AI Robots

For traders seeking to navigate volatile sectors like cannabis with data-driven precision, Tickeron's Trending AI Robots page offers a curated view of top-performing algorithmic trading bots. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across diverse strategies and timeframes. The Trending AI Robots section highlights only those bots demonstrating the most relevant and consistent performance metrics, allowing users to quickly identify strategies aligned with current market conditions. Whether focused on short-term momentum, swing trading, or longer-term trend following, these bots provide a quantitative edge. Exploring the Trending AI Robots page can help traders discover AI-driven approaches tailored to stocks experiencing significant price movements like TRLV.

TRLV Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors will be critical for TRLV's trajectory. The company's next earnings report, estimated for early August 2026, will provide updated visibility on revenue growth, margin trends, and the ongoing impact of 280E tax relief. Investors should monitor any updates on the share repurchase program's execution pace and remaining authorization. Federal cannabis reform discussions, including potential progress on the SAFE Banking Act or broader descheduling efforts, remain a macro catalyst for the entire sector. On the competitive front, Trulieve's ability to defend its Florida market share while scaling newer markets will be closely watched. Additionally, the stock's elevated beta of 1.86 suggests continued sensitivity to broader market volatility and sector rotation. Analyst consensus currently stands at a Strong Buy with a 12-month price target of $21.00, implying significant upside from recent levels, though execution risks and regulatory uncertainty remain inherent to the cannabis industry.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for TRLV with price predictions
Jul 02, 2026

TRLV in upward trend: price rose above 50-day moving average on June 29, 2026

TRLV moved above its 50-day moving average on June 29, 2026 date and that indicates a change from a downward trend to an upward trend. In of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 01, 2026. You may want to consider a long position or call options on TRLV as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 139 cases where TRLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for TRLV moved out of overbought territory on June 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Moving Average Convergence Divergence Histogram (MACD) for TRLV turned negative on June 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for TRLV crossed bearishly below the 50-day moving average on July 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TRLV broke above its upper Bollinger Band on June 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.502) is normal, around the industry mean (79.618). P/E Ratio (0.000) is within average values for comparable stocks, (97.708). TRLV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.629). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (1.504) is also within normal values, averaging (95.237).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.11B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 2%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 13%. CPHI experienced the highest price growth at 15%, while RGC experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 43%. For the same stocks of the Industry, the average monthly volume growth was 63% and the average quarterly volume growth was 15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 66
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 3 (-100 ... +100)
View a ticker or compare two or three
TRLV
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Details
Why Trulieve Cannabis Corp. (TRLV) Stock Is Up +42.6% in the Last 30 Days